online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 6 of 14
ECPB 2018, 83(3): 40–51
Research articles

The Influence of New Antitumor 4-Thiazolidinone Derivatives in Complex with PEG-Containing Polymeric Carrier on Prooxidant- Antioxidant Status in Liver, Heart and Kidney Tissues of Rats


Introduction. Synthetic heterocyclic 4-thiazolidinone derivatives demonstrated high cytotoxic potential in vitro and low toxic effect in vivo as compared with doxorubicin’s action. However, poor solubility in water is a serious obstacle in further application of these compounds as anticancer drugs for chemotherapy. In recent years, nanomaterials have been proposed for the encapsulation of anticancer drugs and their delivery to target tumor cells. Most often, the biocompatible hydrophilic polymers decorated with polyethylene glycol decoration are used for the drug delivery. The oxidative stress is considered to be one of the main mechanisms of damaging tissues and organs by nanoparticles.

Purpose. The study was to determine the biochemical criteria of balance in the system of lipid peroxidation and antioxidant activity under the influence of experimental antitumor compounds Les-3288, Les-3833 and Les-3882 in the liver, heart and kidney tissues of rats.

Materials and methods. The 4-thiazolidinones derivatives used in this study (Les-3288, Les-3833 and Les-3882) were synthesized at the Department of Pharmaceutical, Organic and Bioorganic Chemistry of Danylo Halytsky Lviv National Medical University. The nanocarrier was synthesized at the Department of Organic Chemistry of Lviv National Polytechnic University. It is a surface-active polymer of a comb-like structure that contains the hydrophilic polyethylene glycol chains grafted to the main hydrophobic chain. It was found that in aqueous solutions the amphiphilic polymer forms the nanocomplexes with the micelle-shaped structure providing an ability to solubilize water-insoluble 4-thiazolidinones derivatives. Laboratory rats had been given daily the compounds Les-3882, Les-3288 and Les-3833 for 20 days, as well as their complexes with polymeric nanocarrier. Doses for antitumor compounds were 10 % of LD50: doxorubicin 5.5 mg/kg, Les-3882 and Les-3833 - 10.7 mg/kg, Les-3288 - 24.3 mg/kg.

Results. The obtained results showed that the experimental antitumor drugs Les-3288, Les-3833 and Les-3882 which had been given during 20 days to rats have led to the balance disturbance in the system of lipid peroxidation and antioxidant activity. These changes have been manifested as the enhancement of lipid peroxidation reactions and the exhaustion of the antioxidant system in liver, heart and kidney tissues of the experimental rats. In general, the Les-3288, Les-3833 and Les-3882 compounds showed less destructive actions, comparing with a doxorubicin’s effect towards a disturbance of equilibrium in the lipid peroxidation and antioxidant activity systems, although the mechanism of such influence for each compound looks to be different. According to the results of activation of the lipid peroxidation and the decrease of the antioxidant activity in tissues, the studied compounds can be placed in the following sequence: doxorubicin >> Les-3833> Les-3288 >> Les-3882. It can be concluded that all studied antitumor compounds in complexes with the polymeric nanocarrier have caused less destructive and toxic effects on the lipid peroxidation and the activity of antioxidant enzymes.

Conclusions. Thus, the correspondence of the protection of antioxidant systems in the investigated organs to the level of lipid peroxidation processes is the most informative indicator for estimating the mechanisms of tissue damage by toxic antitumor agents. The balance in the system of the lipid peroxidation and the antioxidant activity can be used as a criteria of toxic effects of anticancer compounds in vivo, and the indicators of the oxidative metabolism are crucial for the development of metabolic disorders, toxicological damage in tissues under the influence of antitumor drugs.

Article recieved: 03.08.2018

Keywords: 4-thiazolidinone derivatives, doxorubicin, lipid peroxidation, antioxidant activity, superoxide dismutase, catalase, glutathione peroxidase

Full text: PDF (Ukr) 296K

  1. 1. Ali R, Mirza Z, Ashraf GM, Kamal MA, Ansari SA, Damanhouri GA et al. New Anticancer Agents: Recent Developments in Tumor Therapy. Anticancer Research. 2012;32:2999-3006.
  2. 2. Garattini S and Bertele V. Efficacy, safety, and cost of new anticancer drugs. BMJ. 2002;325(7358):269-71.
  3. 3. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485- 95.
  4. 4. Havrylyuk DYa, Zimenkovsky BS, Lesyk RB, Roman OM. Patent UA u201114202, No 69857. 3-{2-(5-(3,5-diaryl)-4,5-dihydropyrazol-1-yl)-4-oxo-4H-thiazol-5-iliden}-1,3-dihydroindol- 2-ones, that possess anticancer activity. Publ. 10.05.2012, Bull.19.
  5. 5. Коbylinska L, Boiko N, Panchuk R, Grytsyna I, Klyuchivska O, Biletska L et al. Putative anticancer potential of novel 4-thiazolidinone derivatives: cytotoxicity towards rat C6 glioma in vitro and correlation of general toxicity with balance of free radical oxidation in rats. Croatian Med J. 2016;57(2):150-63.
  6. 8. Kоbylinska LI, Havrylyuk DYa, Mitina NE, Zаichenko AS, Lesyk RB, Zіmenkovskyi BS et al. Biochemical indicators of nephrotoxicity in blood serum of rats treated with novel 4-thiazolidinone derivatives or their complexes with polyethyleneglycol-containing nanoscale polymeric carrier. Ukr Biochem J. 2016;88(1):51-60.
  7. 9. Savjani K, Gajjar A and Savjani J. Drug Solubility: Importance and Enhancement Techniques. ISRN Pharmaceutics. 2012;12:1-10. doi:10.5402/2012/195727.
  8. 10. Narvekar M, Hui Yi, Xue HY, Eoh JY, Wong HL. Nanocarrier for Poorly Water-Soluble Anticancer Drugs – Barriers of Translation and Solutions. AAPS PharmSciTech. 2014;15(4):822-33.
  9. 11. Bunkera A. Poly(ethylene glycol) in drug delivery, why does it work, and can we do better? All atom molecular dynamics simulation provides some answers. Physics Procedia. 2012;34:24-33.
  10. 12. Mishra P, Nayak B, Dey RK. PEGylation in anti- cancer therapy: An overview. Asian Journal of Pharmaceutical Sciences. 2016;11:337-48.
  11. 13. Fleury C, Mignotte B, Vayssière J-C. Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002;84:131-41.
  12. 14. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787-95.
  13. 15. Komarova EA, Gudkov AV. Suppression of p53: a new approach to overcome side effects of antitumor therapy. Biochemistry. 2000;65:41-8.
  14. 16. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. The Journal of Biological Chemistry. 2003;278(36):33714-23.
  15. 17. Tymochko MPh, Kobylinska LI. Free radical reactions and their metabolic role. Medical Chemistry. 1999;1(1):19-25.
  16. 18. Kobylinska LI, Tymochko MF. The role of prooxidant-antioxidant balance in the adaptational reactions of organism. Exp and Clin Physiol and Biochem. 2000;4:52-8.
  17. 19. Stefanov OV. Preclinical studies of medicines. Methodological recommendations. Kiev; 2001. 527 p.
  18. 20. Riabtseva A, Mitina N, Boiko N, Garasevich S, Yanchuk I, Stoika R et al. Structural and Colloidal-Chemical Characteristics of Nanosized Drug Delivery Systems Based on Pegylated Comb-like Carriers. Chemistry and Chemical Technology. 2012;6(3):291-5.
  19. 22. Timirbulatov RR, Seleznev EI. A method for increasing the intensity of free radical oxidation of lipid-containing blood components and its diagnostic significance. Lab Delo. 1981;4:209-11.
  20. 23. Kostyuk VA, Potapovich AI, Kovaleva ZhM. A simple and sensitive method for determining SOD, based on the reaction of oxidation of quercitin. Questions of Medical Chemistry. 1990;36(2):88-91.
  21. 24. Moin VM. A simple and specific method for determining the activity of glutathione peroxidase in erythrocytes. Lab Delo. 1986;2:724-7.
  22. 25. Korolyuk MA, Ivanova LI, Mayorova IG. Method of determination of activity of catalase. Lab Delo. 1988;1:16-9).
  23. 26. Kobylinska L, Lesyk R, Stoyka R, Zimenkovskyi B. A search for mechanisms of imbalance of the metabolic indicators and natural detoxification at the action of new 4-thiazolidinone derivatives possessing anti-neoplastic activity. Exp and Clin Physiol and Biochem. 2016;3(75):24-34.

Програмування -